Bayer commits $2.2B to US pharma plant, aligning with Trump reshoring push

Bayer announced a $2.2 billion investment in a US pharmaceutical production site, supporting the Trump administration's goal to onshore drug manufacturing. The move signals a strategic shift in supply chain resilience and may influence future pharma investment patterns. Details on the specific site and timeline remain undisclosed.